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Elevated amyloid-b peptide (Ab) in brain contributes to Alzheimer’s disease (AD) pathogenesis. We
demonstrated the presence of exosome-associated Ab in the cerebrospinal ﬂuid (CSF) of cynomolgus
monkeys and APP transgenic mice. The levels of exosome-associated Ab notably decreased in the CSF
of aging animals. We also determined that neuronal exosomes, but not glial exosomes, had
abundant glycosphingolipids and could capture Ab. Infusion of neuronal exosomes into brains of
APP transgenic mice decreased Ab and amyloid depositions, similarly to what reported previously
on neuroblastoma-derived exosomes. These ﬁndings highlight the role of neuronal exosomes in
Ab clearance, and suggest that their downregulation might relate to Ab accumulation and,
ultimately, the development of AD pathology.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A pathological feature of Alzheimer’s disease (AD) is the pres-
ence of senile plaques, extracellular amyloid depositions of amy-
loid-b peptide (Ab). Ab is generated by the processing of amyloid
precursor protein (APP), and is maintained at a steady state in nor-
mal brain. However, disruption of the balance in Ab metabolism
contributes to the formation of toxic Ab assemblies and amyloid
depositions, which are linked to AD pathogenesis. Recently, exo-
somes, a subtype of secreted vesicles, were reported to associate
with extracellular Ab in cultures of APP-expressing neuroblastomacells [1,2]. Similarly, our previous study both in vitro and in vivo
demonstrated that exosomes released from neuroblastoma N2a
can bind Ab on their surface glycosphingolipids (GSLs) and these
Ab-bound exosomes are then internalized bymicroglia for degrada-
tion [3,4]. This suggests that N2a-derived exosomes may act for Ab
elimination in brain. However, it remains unclear whether the
exosomes,which originate fromcells resident in the central nervous
system, also contribute to Abmetabolism.
2. Materials and methods
2.1. Animals
Wild type C57BL/6 mice and mice expressing the human APP
bearing the Swedish and Indiana (KM670/671NL, V717F)
mutations (J20) were obtained from SLC Inc. (Hamamatsu, Japan)
and the Jackson Laboratory (Bar Harbor, ME), respectively. All
K. Yuyama et al. / FEBS Letters 589 (2015) 84–88 85animal procedures were approved by the Animal Care Committees
of Hokkaido University.
2.2. Monkey and murine samples
Cynomolgus monkeys (Macaca fascicularis) were housed at the
Tsukuba Primate Research Center (TPRC), National Institute of
Biomedical Innovation (NIBIO), Ibaraki, Japan. Monkey CSF samples
were obtained by lumbar puncture. Nine CSF samples were from
young monkeys (4–8 years old), 8 from adult monkeys
(11–21 years old), and 4 from aged monkeys (24–36 years old).
Each CSF sample was used for exosome isolation without prior
freezing. The parietal lobes of 20 monkeys were used for Western
blotting and ELISA. All animals were bred and maintained in an
air-conditioned room at the TPRC with controlled illumination
(12 h light/12 h dark), temperature (25 ± 2 C), humidity
(60 ± 5%), and ventilation (10 cycles/h), and were given 70 g of
commercial food and 100 g of apples daily, with unlimited access
to tap water [5]. The maintenance of animals was conducted
according to rules of the TPRC at NIBIO regarding the care, use,
and biohazard countermeasures of laboratory animals. All animal
experiments were conducted according to the guidelines of the
Animal Care and Use Committee of the NIBIO, Japan.
Mouse CSF was sampled from the cisterna magna following
protocols previously reported [6]. Each 50 ll of CSF was collected
from 2-month-old C57BL/6 mice or APP mice at the indicated ages.
2.3. Cell cultures
Primary neuron cultures were prepared from the cerebral corti-
ces of mouse brains on embryonic day 15 as described previously
[3]. Primary glial cultures were prepared from the mouse cortices
according to published methods with minor modiﬁcations [7,8].
Brieﬂy, the neocortex was removed from each 2-day-old mouse
pup, dissociated in a dissociation solution (Sumitomo Bakelite,
Tokyo, Japan), and plated in DMEM and 10% fetal bovine serum
(FBS). After being cultured for 14 days, the microglia were
detached by shaking, and the separate cells were cultured in
DMEM/5% FBS. The astrocytes remaining in the ﬂasks were cul-
tured in DMEM/10% FBS. The resultant glial cells were cultured
for two days and used for further analysis.
2.4. Exosome isolation
Exosomes were prepared from supernatants of primary cultures
as described previously [3]. Brieﬂy, after culture of cells for one
day, the culture supernatants were sequentially centrifuged at
2000g for 10 min, and at 10000g for 30 min, and at 100000g
for 1 h to obtain exosomes as pellets. Using this same method,
exosomes were also isolated from the CSF samples of APP mice
or monkeys.
2.5. Electron microscopy
Exosomes were stained with phosphotungstic acid. For immu-
nolabeling, the exosomes were incubated with anti-Ab antibody
(4G8) then 10 nm gold-coupled anti-IgG. Images were taken with
JEM-ARM200F (JEOL Ltd., Tokyo, Japan) transmission electron
microscope.
2.6. Western blotting
To detect target proteins, we employed monoclonal antibodies
against Alix, GM130, Transferrin receptor (BD Biosciences), and
Ab (6E10, Signet, Dedham, MA), and a polyclonal antibodyagainst ﬂottilin-1 (Santa Cruz Biotechnology). Ganglioside GM1,
was detected by cholera toxin B subunit (Sigma).
2.7. Fluorescence labeling for the exosomes
Labeling of the exosomes was performed using PKH26 (Sigma)
as described previously [3].
2.8. Analysis of particle size and number
The exosomes collected from primary cultures of neurons and
CSF samples were suspended in PBS, and a qNano System (Izon Sci-
ence, Ltd) employed to analyze the particle size and densities.
CPC100 was used as the calibration sample.
2.9. Exosome administration into mouse brains
The experiment was performed as previously described [4].
Brieﬂy, mice were continuously treated with exosomes (2 mg pro-
tein/ml) or PBS by Alzet minipump at 0.25 ll/h for 14 days. The
Brain Infusion Kit was implanted into the right hippocampus using
a stereotactic instrument. One hemibrain was ﬁxed for immuno-
histochemistry, and the other was frozen for use in ELISA.
2.10. Immunohistochemistry and thioﬂavin-S (ThS) staining
Immunostaining and ThS staining were performed as described
previously [4].
2.11. Ab ELISA
Ab1–40 and Ab1–42 levels were determined using an ELISA kit
(Wako, Osaka, Japan) as previously described [4].
2.12. Measurement of glycosphingolipids (GSLs)
Levels of GSLs in the exosomes of primary cultures were
measured as described previously [4]. After their extraction, the
GSLs were enzymatically digested with EGCase I and II, further
puriﬁed by glycoblotting, then analyzed by MALDI-TOF MS.
2.13. Endoglycosylceramidase (EGCase)
Exosomes (1 mg protein/ml) were incubated with 0.5 U/ml
EGCase II (Takara Bio Inc., Shiga, Japan) at 37 C for 15 h in PBS.
2.14. Thioﬂavin assay
Thioﬂavin-T (ThT) assay was performed as previously published
[4].
2.15. Ab binding assay
Fluorescent Ab1–42 (25 lM) was incubated with the PKH26-
labeled exosomes (treated with or without EGCase) in serum-free
medium at 37 C for 5 h. The exosomes and bound Ab were
observed after wash out free Ab.
3. Results
3.1. Exosomes associate with Ab in the CSF of non-human primates
The non-human primate cynomolgus monkey is widely used for
AD-related preclinical studies [9]. In the monkey brains, Ab naturally
increases in an age-dependent manner (Fig. 1A) as described in the
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Fig. 1. Exosomes associate with Ab in the CSF of cynomolgus monkeys. (A) Ab levels in the brain tissues were analyzed. Values are presented as the mean ± S.D. (Young, n = 5;
Adult, n = 6; Aged, n = 9, ⁄P < 0.05, ⁄⁄⁄P < 0.001). (B) Images of the exosome fraction. Bars: 1 lm in left panel, 100 nm in right panel. (C) Particle size distribution of the exosome
fraction. (D) Western blotting of the exosomes. Alix, ﬂotillin-1(Flot-1), and ganglioside GM1 (GM1) as exosome markers; transferrin receptor (TfR) and GM130 as negative
markers. BT, brain tissues (E) Ab levels in the CSF-exosomes were measured. Values are presented as the mean ± S.D. (Young, n = 9; Adult, n = 8; Aged, n = 4, ⁄P < 0.05).
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originating from brain cells against Ab metabolism, we isolated
exosomes from monkey CSF, then measured the Ab levels in the
exosome fractions. The CSF-derived exosomes were conﬁrmed by
electron microscopy to mainly consist of small membrane vesicles
50–200 nm in diameter (Fig. 1B), similar to previously described
[12]. The exosome size was further veriﬁed by a nanoparticle
analyzer, which found the sizes to range from 100 to 200 nm
(Fig. 1C). The exosomal markers were also identiﬁed in the
CSF-exosome fractions (Fig. 1D). We found that Ab was detectable
in all CSF-derived exosome fractions but that the levels of
exosome-associated Abwere markedly lower in the adult and aged
brains compared to the young subjects (Fig. 1E). The level of free
Ab, which was not associated with the exosomes in the CSF,
declined only in the aged brains (Supplemental Fig. 1). These
results suggest that the function of exosomes transporting Ab in
the central nervous system may deteriorate with age (>11-year-
old).
3.2. Age-related alterations in the number of exosomes in primary
neuronal cultures and APP transgenic mouse CSF
Neuronal cell cultures are widely used as models to study the
molecular mechanisms of aging. We collected the exosomes from
primary cultures of cortical neurons at 1, 7, or 14 day in vitro(DIV) and found that there were signiﬁcant reductions in the num-
ber of particles at DIV14 compared to those at DIV1 or DIV7 (Sup-
plemental Fig. 2A). While exosomal GSLs, especially sialylated
GSLs, kept rising up to DIV14 (Supplemental Fig. 2B). These suggest
that a reduction in exosome release might occur during aging, with
maintaining the capacity of individual exosome to bind with Ab.
To investigatewhether the above ﬁndings in the non-humanpri-
mates and in the neuronal cultures are also observed in APP trans-
genic mice, we collected the exosomes from CSF of 13-month-old
APP mice and examined them for the presence of Ab, using western
blot analysis and electronmicroscopywith immunolabeling (Fig. 2A
and B). We then quantiﬁed the exosomes isolated from APP mouse
CSF at ages 2 to 23 months. Compared to the number of CSF-exo-
somes isolated from young mice (2–3 months old), the densities
of exosomes in mice aged 6–7 months decreased; these low levels
were maintained through 12–13 months of age, thereafter drasti-
cally declined in 23-month-old mice (Fig. 2C). We also showed
marked reduction in Ab levels in the CSF-exosomes between 2-
and 23-month-old APP transgenic mice (2.19 ± 0.36 nM and
0.015 ± 0.012 nM, respectively), in accordance with those in the
monkey CSF with age. In contrast, Ab levels in the brain tissues
continued rising in mice from ages 6–7 months to 23 months. The
above data raised the possibility that endogenous exosomes
released from brain cells may play a role in modulating Ab
metabolism.
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Fig. 2. Age-dependent alterations in the concentrations of exosomes from APP
mouse CSF. (A) Ab in whole brain tissues (5 lg protein) and in exosomes isolated
from the CSF (50 ll) of 13-month-old APP mice was detected. (B) Exosomes derived
from 13-month-old APP mouse CSF were negatively stained and immunolabeled for
Ab. Scale bar, 50 nm. (C) CSF was collected from APP mice at the indicated ages, and
the densities of the exosomes were measured. Ab levels in whole brains of APP mice
were quantiﬁed. Values of Ab levels are presented as the mean ± S.D. (n = 5).
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with Ab
We previously determined that the enriched glycans of the GSLs
are essential for Ab binding and assembly on N2a-exosomes [3]. To
examine this in our currentmodel, we collected exosomes from pri-
mary cultures of rodent cortical neurons, astrocytes and microglia,
and determined the proﬁles of their GSL-derived glycans and their
propensity for trapping Ab. We found that there were signiﬁcantly
more GSLs in neuronal exosomes than in exosomes from glial cells
(Fig. 3A). Sialylated GSLs were also abundant in the neuronalA B
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Fig. 3. GSL-enriched neuronal exosomes associate with Ab. Exosomes were collected fro
amounts of GSL-glycans and the number of sialic acid moieties in the exosomes were me
exposure. Bar, 100 lm. (C) After a 5 h incubation, ThT ﬂuorescence intensities were detec
Each column represents the average ± S.D. of four values.exosomes; in particular, trisialoganglioside GT1 was found in only
neuronal exosomes (Supplemental Table 1). Ganglioside GM1,
which has been reported to bind Ab in AD brains, was also highly
enriched in neuronal exosomes (Supplemental Fig. 3 and Table 1).
Accordingly, neuronal exosomes, but not glial exosomes, associated
with Ab (Fig. 3B). In ThT assays for amyloid ﬁbril detection, ﬂuores-
cence intensities were enhanced after a 5 h-incubation with Ab
(Fig. 3C). Pretreatment of the neuronal exosomes with EGCase lar-
gely prevented the ThT ﬂuorescence (Fig. 3C), indicating that the
GSLs abundant in the neuronal exosomes contributed to the
potency of the exosomes to bind Ab.
3.4. Administration of neuronal exosomes decreases Ab pathology in
APP mouse brains
To assess the effect of the exosomes derived from primary neu-
rons on amyloid pathology, we continuously administered the exo-
somes into the right hippocampus of 13-month-old APP mice. We
found that the exosomes induced marked reductions in Ab immu-
noreactive burdens (Fig. 4A and B) and ThS-positive plaques
(Fig. 4C) in the treated hippocampus. Tissue levels of Abs were also
signiﬁcantly decreased following the exosome infusion (Fig. 4D).
These ﬁndings demonstrate that the treatment with neuronal
exosomes effectively ameliorates Ab pathology in APP mice, sug-
gesting a novel role for neuronal exosomes in clearing Ab in brain.
4. Discussion
Our study shown here demonstrated that exosomes are pre-
sented in monkey and murine CSF. The exosomes collected from
monkey CSF at all ages contained Ab (Fig. 1E), demonstrating that
endogenous exosomes are also coupled with Ab. In addition, the
numbers of exosomes in the CSF of APP transgenic mice changed
in an age dependent manner (Fig. 2C). It remains unclear which
age-related factors would modulate exosome numbers, although
the impairment of endocytic transport might be a potent possibil-
ity. Endocytic disturbances, such as endosome enlargement, are
observed in aged monkey brains, with concomitant highersnorueNAstrocytes
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Fig. 4. Neuronal exosomes decreases Ab pathology in APP mouse brains. Neuronal exosomes were infused into the hippocampus of 13-month-old APP mice for 14 days. (A)
Image of Ab-stained hippocampal section. Bar, 200 lm. (B and C) Ab-immunopositive areas (B) and the numbers of ThS-positive plaques (C) in each hippocampal region were
measured (n = 4 animals, 2 sections per brain; ⁄⁄P < 0.01). (D) Hippocampal Abs were analyzed by ELISA. (n = 5 animals; ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
88 K. Yuyama et al. / FEBS Letters 589 (2015) 84–88expression of Rab GTPases, which are responsible for the endo-
some transport [13,14]. In addition, the dysfunction of dynein, a
microtubule-associated protein active in endosome trafﬁcking,
has also been observed in aged monkey brains [13]. Notably,
knockdown of dynein reduced exosome release from N2a cells
[13]. Considering the appearance of endocytic pathology in early
AD pathogenesis [15,16], disturbance of intracellular transport
might mediate the reduction of exosomes, eventually leading to
Ab accumulation in the aged brains.
Our study reported here clearly demonstrated that intracerebral
infusion of neuronal exosomes results in decreases in Ab levels and
amyloid deposition in the brains of APP transgenicmice (Fig. 4). It is
noteworthy that another pathological agent of AD, tau, can be
collected from the CSF-exosomes of early AD patients [17], raising
the possibility that exosomes modulate multiple factors associated
with AD pathogenesis. The improvement of endogenous exosome
generation might serve as a novel approach for treating or preserv-
ing AD.
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